Skip to main content

Amgen to continue to seek full approval of Lumakras cancer drug after FDA panel votes against it

Amgen will continue to seek full approval for its Lumakras cancer drug as a treatment for a form of lung cancer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.